FLOW SUMMARY

Market flows on Gilead Sciences reveal an overall positive bias. The Put/Call Ratio at 0.79 for the August 7, 2026 expiration indicates a dominance of call options, signaling speculative and offensive sentiment from market participants. This risk appetite is confirmed by call volume exceeding put volume. Concurrently, Dark Pool activity (FINRA ATS) recorded moderate but significant volume of 8.7 million shares traded for a notional value of $0.68 billion over the past week. This OTC volume, while not exceptional, demonstrates active institutional presence in the stock. In aggregate, flow signals indicate a POSITIVE bias, suggesting sustained interest in Gilead Sciences.

TECHNICAL AND VOLUMETRIC STRUCTURE

After a consolidation period around $130, Gilead Sciences is showing a significant rebound. The current price of $135.25 represents an intraday gain of 3.13%, accompanied by a trading volume of over 10 million shares, which is 156% of its monthly average. This strong buying pressure, validated by high volume, lends credibility to the bullish move. The price is now trading above its key moving averages, with the SMA(20) at $132.18 and the SMA(200) at $130.67, confirming positive short- and medium-term momentum. The RSI(14) at 56.60 indicates healthy momentum, with room for progression before reaching overbought territory. Key technical levels to watch are resistance at $140.61 (1-month) and $155.38 (6-month), while support levels are at $123.67 (1-month) and $120.60 (6-month).

SCENARIOS & CATALYSTS

On the primary horizon (medium term, 20-60 business days):

BULLISH SCENARIO (65% probability): Gilead Sciences continues its revaluation towards $155.00, driven by quarterly results exceeding expectations and institutional buying flow. The analyst consensus, with an average target of $157.15, provides a solid fundamental anchor. The generalized BULLISH market regime (S&P 500 > MA50 > MA200) and a VIX at 16.50 (risk-on) provide a favorable environment. Catalysts include further pipeline advancements, strategic acquisitions (such as the Ouro Medicines buyout), and continuous margin improvement.

BASE / NEUTRAL SCENARIO (25% probability): The stock consolidates between $130.00 and $140.00. Despite good results, persistent macro-structural risks (geopolitical, energy, monetary) and relative underperformance against the S&P 500 over 5 days and 3 months could dampen momentum. The market may await more significant catalysts to justify a break of key resistances. A lack of major news or a deterioration in sector sentiment could keep the stock within a range.

BEARISH SCENARIO (10% probability): A break below the support at $123.67 (1-month) or $120.60 (6-month) would invalidate the bullish scenario. This scenario could be triggered by a more pronounced macroeconomic deterioration, a sector rotation unfavorable to biopharmaceutical stocks, or pipeline disappointments. A sudden increase in global risk aversion, signaled by a rise in the VIX or a flight to safety (strong DXY, rising TLT), could also weigh on the stock.

AEGIS VERDICT

In a BULLISH regime (SPY > MA50 > MA200), this BULLISH signal on Gilead Sciences is based on solid post-earnings fundamentals and institutional buying flow. Macro risk remains moderate to high, but the Gold/Silver ratio indicates a generalized 'risk-on' sentiment. A Risk/Reward ratio of 1.67:1 is required. The signal triggers on a daily close above $135.00. The first target (TP1) is set at $145.00, allowing for partial profit taking. The final target (TP2) is $155.00, in line with the 6-month resistance and analyst consensus. Recommended sizing: standard (1x). Potential catalysts include new drug approvals, improved market sentiment for the biopharmaceutical sector, and effective management of geopolitical risks. Invalidation of the scenario would occur on a close below $123.00 or a significant deterioration of the overall macroeconomic context.